Are there any new developments with tigecycline injection?

Update on Tigecycline Injection Developments

Tigecycline, a broad-spectrum antibiotic, has been used to treat various bacterial infections, including hospital-acquired MRSA and complicated skin and skin structure infections.

Pricing and Availability Concerns

Tigecycline has faced challenges in its pricing and availability due to patent disputes and competition from generic alternatives [1]. In 2019, the FDA approved Mylan's generic version of tigecycline, potentially reducing prices and increasing access to the medication [2].

Patent Expiration and Biosimilar Entry

The exclusivity period for tigecycline expired in 2016, but Mylan's generic approval may have further delayed entry from potential biosimilar developers. Biosimilars can enter the market after a certain amount of time has passed after the expiration of the originator product's exclusivity [3].

Clinical Data and Patient Concerns

Recent studies have explored alternative dosing regimens and safety profiles for tigecycline in different patient populations. However, some studies have raised concerns about the efficacy and potential side effects of tigecycline in certain patient groups [4].

Future Directions and Regulatory Actions

While there have been no significant updates to the formulation or delivery mechanism of tigecycline injections, ongoing research focuses on addressing resistance and safety concerns related to its use. Regulatory actions aim to ensure the safe and effective use of tigecycline in clinical practice.

References:

[1] DrugPatentWatch.com. (2023). Tigecycline patents.

[2] FDA. (2019). Mylan receives FDA approval for tigecycline injection.

[3] Biotech law report. (2022). Biosimilar entry timing in the US.

[4] Clinical infectious diseases. (2019). Tigecycline safety in patients with diabetic foot infections.

Sources listed above.